- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- February 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- January 2026
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- October 2025
- 250 Pages
Global
From €4027EUR$4,490USD£3,483GBP
- Report
- November 2025
- 200 Pages
Global
From €7130EUR$7,950USD£6,168GBP
- Report
- March 2026
- 287 Pages
Global
From €5246EUR$5,850USD£4,539GBP
- Report
- March 2026
- 294 Pages
Global
From €5246EUR$5,850USD£4,539GBP
- Report
- March 2026
- 282 Pages
Global
From €5246EUR$5,850USD£4,539GBP
- Report
- March 2026
- 383 Pages
Global
From €5246EUR$5,850USD£4,539GBP
- Report
- March 2026
- 217 Pages
Global
From €5246EUR$5,850USD£4,539GBP
- Report
- March 2026
- 172 Pages
Global
From €5246EUR$5,850USD£4,539GBP
- Report
- March 2026
- 275 Pages
Global
From €5246EUR$5,850USD£4,539GBP

The CAS9 market is a subset of the genomics industry that focuses on the development and use of the CRISPR-Cas9 gene-editing technology. This technology is used to modify the genetic code of living organisms, allowing for the manipulation of genes and the potential to create new treatments for diseases. CAS9 is a powerful tool for researchers, allowing them to make precise changes to the genetic code of organisms.
The CAS9 market is growing rapidly, with many companies investing in the technology and its applications. Companies such as Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Caribou Biosciences are leading the way in developing and commercializing the technology. Other companies such as Horizon Discovery, Synthego, and Twist Bioscience are also investing in the CAS9 market, providing tools and services to researchers. Show Less Read more